- Stocks
- Pharma & Healthcare
- Alembic Pharmaceuticals
Alembic Pharmaceuticals share price
NSE: APLLTDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Alembic Pharmaceuticals at a glance
Alembic Pharmaceuticals (NSE: APLLTD) closed at ₹785.00 on 22 Oct 2026, down 0.41% on the day. With a market capitalisation of ₹15,357 Cr, it ranks 414th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 22.9× trailing earnings, against a return on equity of 11.2% in FY25. Over the past year the share price has fallen 14.0%. Its 52-week range is ₹635.80 (23 Mar 2026) to ₹998.00 (4 Nov 2025); the last close is 21.3% below the high. Promoters held 69.87% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹15,357 CrRank 414 on NSE
- P/E (trailing)
- 22.9×
- Price to book
- 3.52×FY25
- ROE
- 11.2%FY25
- ROCE
- 14.4%FY25
- Debt to equity
- 0.23FY25
- Net profit margin
- 8.7%FY25
- Book value / share
- ₹264.10FY25
- Dividend payout
- 37.1%FY25
- 52-week high
- ₹998.004 Nov 2025
- 52-week low
- ₹635.8023 Mar 2026
- 1-year return
- −14.0%
- RSI (14-day)
- 38.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.41% | −1.1% | −7.2% | −3.1% | −14.0% |
Alembic Pharmaceuticals financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹4,606 Cr | ₹5,393 Cr | ₹5,306 Cr | ₹5,653 Cr | ₹6,229 Cr | ₹6,672 Cr |
| Operating profit | ₹1,043 Cr | ₹1,368 Cr | ₹620 Cr | ₹386 Cr | ₹633 Cr | ₹693 Cr |
| Net profit | ₹801 Cr | ₹1,115 Cr | ₹516 Cr | ₹373 Cr | ₹617 Cr | ₹581 Cr |
| EPS (₹) | ₹44.00 | ₹61.00 | ₹27.00 | ₹17.00 | ₹31.00 | ₹30.00 |
| Cash from operations | ₹449 Cr | ₹1,463 Cr | ₹552 Cr | ₹724 Cr | ₹803 Cr | ₹88 Cr |
| Total debt | ₹887 Cr | ₹200 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹3,219 Cr | ₹5,128 Cr | ₹5,238 Cr | ₹4,370 Cr | ₹4,818 Cr | ₹5,191 Cr |
Alembic Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.67% | 69.67% | 69.74% | 69.74% | 69.74% | 69.87% |
| Foreign institutions | 3.94% | 3.96% | 4.05% | 4.24% | 4.25% | 4.18% |
| Domestic institutions | 16.43% | 16.46% | 16.30% | 16.17% | 16.18% | 15.94% |
| Non-institutions | 9.96% | 9.90% | 9.92% | 9.85% | 9.83% | 10.01% |
Alembic Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Alembic Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ONESOURCEOnesource Specialty Pharma | ₹1,378.00 | +1.64% | −25.1% | ₹15,796 Cr | — | −1.3% |
| ALIVUSAlivus Life Sciences | ₹1,272.00 | +0.82% | +37.5% | ₹15,576 Cr | 27.7 | 17.2% |
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,537 Cr | 25.3 | 15.9% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −0.41% | −14.0% | ₹15,357 Cr | 22.9 | 11.2% |
| ASTRAZENAstraZeneca Pharma India | ₹6,056.00 | −0.38% | −33.5% | ₹15,252 Cr | 80.9 | 15.0% |
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹15,037 Cr | 47 | 6.5% |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,852 Cr | 100 | 6.6% |
Ask anything about Alembic Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against APLLTD's own history. Try: “Why has APLLTD moved over the last three months?” · “Backtest a 50-day moving-average crossover on APLLTD over five years” · “Compare APLLTD with ONESOURCE on margins and valuation”
Frequently asked questions about Alembic Pharmaceuticals
What is the share price of Alembic Pharmaceuticals today?
Alembic Pharmaceuticals (NSE: APLLTD) last closed at ₹785.00 on 22 Oct 2026. Its 52-week high is ₹998.00 and its 52-week low is ₹635.80.
What is the market cap of Alembic Pharmaceuticals?
Alembic Pharmaceuticals' market capitalisation is ₹15,357 Cr (₹15,357 Cr) at the 22 Oct 2026 close, ranking 414th among the NSE companies Pivot tracks.
What is the P/E ratio of Alembic Pharmaceuticals?
Alembic Pharmaceuticals trades at a trailing P/E of 22.9. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 47.
What is the ROE and ROCE of Alembic Pharmaceuticals?
Return on equity was 11.2% in FY25 and return on capital employed was 14.4% in FY25 (consolidated figures).
Is Alembic Pharmaceuticals a debt-free company?
No. Alembic Pharmaceuticals' debt-to-equity ratio was 0.23 in FY25, with total debt of ₹0 Cr.
How has Alembic Pharmaceuticals stock performed over the last year?
Alembic Pharmaceuticals' share price has fallen 14.0% over the past year, −3.1% over three months and −7.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Alembic Pharmaceuticals?
As of 30 Jun 2026: promoters 69.87%, foreign institutions 4.18%, domestic institutions 15.94%, non-institutions 10.01%.
Who are Alembic Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Alembic Pharmaceuticals by market cap are Onesource Specialty Pharma, Alivus Life Sciences, Eris Lifesciences, AstraZeneca Pharma India, Syngene International and Dr. Agarwal's Health Care.
Is Alembic Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Alembic Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on APLLTD against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text